<p>PureTech Health plc (LON:PRTC - 獲取免費報告) 的股價在週二下跌了 9.2%。該公司的股價最低曾達到 126 便士，最後交易價為 126 便士。在午盤交易中，共成交了 1,066,844 股，較平均交易量 1,249,921 股下降了 15%。該股票此前收盤價為 138.80 便士。</p>
<p>獲取 <strong>PureTech Health</strong> 的提醒：</p>
<h2>PureTech Health 股票表現</h2>
<p>該公司的債務與股本比率為 6.33，流動比率為 6.59，速動比率為 2.51。該股票的市值為 3.0671 億英鎊，市盈率為-2.74，貝塔值為 1.35。該股票的 50 日移動平均線為 121.85 便士，200 日移動平均線為 125.88 便士。</p>
<h2>PureTech Health 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>PureTech Health plc 是一家臨牀階段的生物製藥公司，專注於開發針對神經、胃腸和免疫系統功能障礙引起的疾病的藥物。該公司正在開發微生物組免疫系統藥物發現平台和針對免疫介導疾病的藥物候選者；以及通過口服膠囊誘導減肥和增強血糖控制的產品。它還在開發用於篩查、診斷和治療神經系統疾病（如注意力缺陷多動障礙、自閉症和抑鬱症）的技術和產品；用於精神疾病的非侵入性神經刺激治療；以及用於精神分裂症的聯合治療。</p>
<h2>特色故事</h2>
<ul>
<li>五隻我們更看好的股票超過 PureTech Health</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 PureTech Health 嗎？</h2>
<p>在你考慮 PureTech Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄建議客户在更廣泛的市場注意到之前立即購買的股票……而 PureTech Health 並不在名單上。</p>
<p>雖然 PureTech Health 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PRTC

PRTCY

<p>PureTech Health (倫敦證券交易所代碼: PRTC) 的股價下跌了 9.2%，至 126 便士，交易量為 1,066,844 股，較平均交易量下降了 15%。該公司的市值為 3.0671 億英鎊，市盈率為 -2.74，債務與股本比率為 6.33。分析師目前對該股票的評級為 “買入”，但並不是頂級推薦。PureTech 專注於開發神經系統、胃腸道和免疫系統疾病的治療方案</p>

<p>PureTech Health plc (LON:PRTC - Get Free Report)'s share price traded down 9.2% on Tuesday . The company traded as low as GBX 126 and last traded at GBX 126. 1,066,844 shares traded hands during mid-day trading, a decline of 15% from the average session volume of 1,249,921 shares. The stock had previously closed at GBX 138.80.</p>
<div class="lb-trans"><p>PureTech Health plc (LON:PRTC - 獲取免費報告) 的股價在週二下跌了 9.2%。該公司的股價最低曾達到 126 便士，最後交易價為 126 便士。在午盤交易中，共成交了 1,066,844 股，較平均交易量 1,249,921 股下降了 15%。該股票此前收盤價為 138.80 便士。</p>
</div><p>Get <strong>PureTech Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>PureTech Health</strong> 的提醒：</p>
</div><h2>PureTech Health Stock Performance</h2>
<div class="lb-trans"><h2>PureTech Health 股票表現</h2>
</div><p>The company has a debt-to-equity ratio of 6.33, a current ratio of 6.59 and a quick ratio of 2.51. The stock has a market capitalization of £306.71 million, a PE ratio of -2.74 and a beta of 1.35. The stock has a 50 day moving average of GBX 121.85 and a two-hundred day moving average of GBX 125.88.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 6.33，流動比率為 6.59，速動比率為 2.51。該股票的市值為 3.0671 億英鎊，市盈率為-2.74，貝塔值為 1.35。該股票的 50 日移動平均線為 121.85 便士，200 日移動平均線為 125.88 便士。</p>
</div><h2>PureTech Health Company Profile</h2>
<div class="lb-trans"><h2>PureTech Health 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.</p>
<div class="lb-trans"><p>PureTech Health plc 是一家臨牀階段的生物製藥公司，專注於開發針對神經、胃腸和免疫系統功能障礙引起的疾病的藥物。該公司正在開發微生物組免疫系統藥物發現平台和針對免疫介導疾病的藥物候選者；以及通過口服膠囊誘導減肥和增強血糖控制的產品。它還在開發用於篩查、診斷和治療神經系統疾病（如注意力缺陷多動障礙、自閉症和抑鬱症）的技術和產品；用於精神疾病的非侵入性神經刺激治療；以及用於精神分裂症的聯合治療。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than PureTech Health</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 PureTech Health</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 PureTech Health 嗎？</h2>
</div><p>Before you consider PureTech Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 PureTech Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄建議客户在更廣泛的市場注意到之前立即購買的股票……而 PureTech Health 並不在名單上。</p>
</div><p>While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 PureTech Health 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

PureTech Health (LON:PRTC) 股價下跌 9.2% - 現在是賣出的時候嗎？